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Abstract. It has previously been demonstrated that peripheral 
blood lymphocytes of healthy women carrying BRCA1 or 
BRCA2 mutations exhibit increased chromosomal radiosen-
sitivity, which is characterized by an enhanced formation of 
micronuclei. These results suggest that the deficient repair of 
DNA double-strand breaks may also occur in breast epithelial 
cells of women exhibiting a reduced expression of wild-type 
BRCA1/BRCA2 proteins due to the presence of germline 
mutations in BRCA1/2 genes. The aim of this study was to 
further investigate in vitro the effects of the reduced expression 
of BRCA1 and BRCA2 in MCF10A human non-tumorigenic 
breast epithelial cells, tentatively mimicking the phenotype 
of heterozygous cells of carriers of BRCA1/2 mutations. By 
lentivirus-mediated RNA interference, the stable reduction of 
BRCA1 and BRCA2 expression at the mRNA and protein level 
was achieved, thus generating the BRCA1i and BRCA2i cell 
lines. In these cells, homologous recombination was impaired, 
as significantly lower yields of RAD51 foci were obtained 
following exposure to 2 Gy ionizing radiation compared to 
the control MCF10A cells (BRCA1i cells, 58% reduction; 
BRCA2i cells, 64% reduction). Moreover, in the BRCA1i and 
BRCA2i cells, a dose-dependent increase in micronuclei was 
observed compared to the cells which were not subjected to 
gene knockdown. Cell viability was also affected by partial 
BRCA1/2 knockdown. On the whole, the findings of this study 
indicated that in cells with a reduced BRCA1 or BRCA2 expres-
sion, the impairment of homologous recombination resulted 
in a >50% decrease in RAD51 foci following irradiation and 
increased chromosomal abnormalities (micronuclei). These 
findings suggest that the healthy breast tissue of BRCA1/2 
mutation carriers may be prone to neoplastic transformation 
upon exposure to diagnostic or therapeutic radiation, and that 
the RAD51 foci assay may be useful for the assessment of the 
functionality of HR repair and radiosensitivity in these women.
Introduction
The risk of developing breast cancer markedly increases 
in individuals carrying a germline mutation in the BRCA1 
or BRCA2 caretaker genes, which are activated in the DNA 
damage response machinery and which exert their activity in 
homologous recombination (HR). HR is a DNA double‑strand 
break (DSB) repair pathway, activated in the S and G2 phases 
of the cell cycle following exposure to genotoxic agents, such 
as ionizing radiation (IR) (1,2).
It has been hypothesized that individuals harboring a 
germline mutation in the BRCA1 and BRCA2 genes may 
exhibit enhanced radiosensitivity and may thus be exposed 
to an increased carcinogenic risk following exposure to IR 
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for therapeutic or diagnostic purposes (3‑19). The authors 
have recently demonstrated an increased radiosensitivity and 
micronucleus formation in peripheral blood lymphocytes of 
healthy women carrying BRCA1 or BRCA2 mutations (18,19). 
These results, obtained in peripheral blood lymphocytes, 
suggested that the deficient repair of DNA DSBs might also 
occur in mammary epithelial cells of women exhibiting a 
reduced expression of wild-type BRCA proteins.
Hence, the main aim of this in vitro study was to assess 
the DNA DSB repair capacity and the formation of chromo-
somal abnormalities in irradiated, non-tumorigenic human 
mammary epithelial cells exhibiting a decreased expression of 
wild-type BRCA1/2 proteins, as may occur in the case of the 
healthy mammary tissue of women harboring heterozygous 
BRCA1/2 mutations. In the MCF10A non-tumorigenic human 
mammary epithelial cell line, by lentivirus-mediated RNA 
interference, the partial reduction of the expression levels of 
BRCA1 and BRCA2 was achieved to levels which may func-
tionally mimic those of mammary cells in heterozygous BRCA 
mutation carriers. In these cells, the repair capacity following 
irradiation was investigated using the RAD51 foci assay, 
which specifically detects DNA DSB repair by the homologous 
recombination pathway. A deficient repair capacity was pheno-
typically confirmed by analyzing chromosomal abnormalities 
with the micronucleus assay and by cell viability testing.
Materials and methods
Cell lines. Mycoplasma-free MCF10A cel ls (cat. 
no. CRL‑10317, freshly obtained from ATCC) were cultured 
in monolayers using equal volumes of DMEM-glutamax 
and F12‑glutamax (Life Technologies; Thermo Fisher 
Scientific) supplemented with 5% fetal calf serum (Invitrogen; 
Thermo Fisher Scientific), antibiotics (50 U/ml penicillin 
and 50 µg/ml streptomycin, Invitrogen; Thermo Fisher 
Scientific), 10 µg/ml insulin (Sigma‑Aldrich), 0.5 µg/ml hydro-
cortison (Sigma‑Aldrich) and 20 ng/ml epidermal growth 
factor (Peprotech). Experiments were performed on cells in 
which BRCA1 and BRCA2 were knocked down (these cells 
are referred to as BRCA1i and BRCA2i cells). RNA inter-
ference (RNAi) was achieved by stable transduction with 
lentiviral vectors harboring DNA sequences encoding short 
hairpin RNAs specific for BRCA1 or BRCA2. In brief, lenti-
viral particles were constructed using pLKO.1-puro vectors 
(Addgene). The RNAi sequences for BRCA1 and BRCA2 were 
5'‑GCC CAC CTA ATT GTA CTG AAT‑3' and 5'‑TAC AAT GTA 
CAC ATG TAA CAC‑3', respectively. A negative control cell 
line, transduced with an empty pLKO.1-puro lentiviral vector 
(hereafter referred to as the control) was also established. 
This is an acknowledged limit of this study, as scrambled 
sequence transduction would have been preferable, though 
according to previous experience, this procedure may target 
unintended mRNAs. Moreover, empty vectors allow for the 
determination of the effects of transduction on cell response 
and gene expression (20). The transduction of the MCF10A 
cells was achieved by the addition of 1 µg/ml DNA, TurboFect 
(1.5 µg/ml, Thermo Fisher Scientific) and polybrene (1 µg/ml, 
Sigma‑Aldrich) to a 30% confluent culture. Cells were grown 
in puromycin‑supplemented DMEM medium (2 µg/ml, 
Life Technologies; Thermo Fisher Scientific) for 15 days to 
obtain stably transduced cell lines. Notably, stable BRCA1 
knockdown by retrovirus-mediated RNAi does not alter the 
non‑tumorigenic phenotype of MCF10A cells (21). According 
to our personal experience, BRCA1/2 knockdown neither 
induces transformation in vitro, nor tumorigenesis in vivo.
Reverse transcription‑quantitative PCR (RT‑qPCR) analysis. 
BRCA1 and BRCA2 mRNA knockdown was evaluated 
by RT-qPCR analysis. Total RNA was extracted using 
RNeasy Mini kits (Qiagen Benelux), following the manu-
facturer's instructions, without optional DNase treatment. 
The RNA concentration and quality were determined using 
a DropSense96 kit (Trinean) before removing contaminating 
DNA with the Heat&Run gDNA removal kit (Articzymes). 
Reverse transcription was achieved with the iScript cDNA 
synthesis kit, following the manufacturer's instructions. A 
total of 5 µl of qPCR reaction contained 10 ng cDNA (total 
RNA equivalents), 2.5 µl SsoAdvanced universal SYBR‑Green 
supermix (Bio‑Rad) and 2.5 µM forward and reverse primers. 
Cycling and detection was performed on a Lightcycler LC480 
(Roche) with 2 min denaturation at 95˚C followed by 45 cycles 
with 5 sec at 95˚C, 30 sec at 60˚C and 1 sec at 72˚C. Melting 
curve analysis was performed to test for non‑specific ampli-
fication. Three biological repeats were performed for each 
amplification. The analysis of relative gene expression was 
performed using a qBase+ platform (Biogazelle), developed 
by Hellemans et al (22), based on the ΔΔCq method by Livak 
and Schmittgen (23).
Western blot analysis. BRCA1 and BRCA2 protein knockdown 
was evaluated by western blot analysis. Protein extraction was 
performed in subconfluent cultures of the control, BRCA1i and 
BRCA2i cells using a tris‑EDTA lysis buffer containing 1% 
NP‑40 and 1% protease inhibitor (Sigma‑Aldrich). For each 
sample, 50 µg protein were loaded together with 25% SDS 
sample buffer (Thermo Fisher Scientific) and 10% dithiothri-
etol (DDT, Sigma‑Aldrich) on a 3‑8% Tris‑Acetate gel (Novex; 
Thermo Fisher Scientific), and run for 5 h at 25 mA. Proteins 
were transferred to a methanol-pretreated PVDF membrane in 
Tris/glycine blotting buffer enriched with 10% methanol for 
16 h at 30 V. Following standard blocking, the membrane was 
incubated overnight at 4˚C with a primary antibody (rabbit 
polyclonal anti-BRCA1, cat. no. 07-434, diluted 1:1,000, 
or monoclonal anti‑BRCA2, cat. no. OP95, diluted 1:500; 
Millipore), together with mouse monoclonal α-actinin (cat. 
no. 05‑384, diluted 1:30,000 Millipore). The membranes 
were washed and incubated for 2 h at room temperature with 
horseradish peroxidase (HRP)‑conjugated secondary anti-
bodies (goat anti-rabbit-HRP, Perbio, cat. no. 31460, diluted 
1:1,000, or goat anti-mouse-HRP, cat. no. 31432, Thermo 
Fisher Scientific, diluted 1:1,000). Visualization was achieved 
with a chemoluminescence kit (Thermo Fisher Scientific), 
and analysis of relative expression at the protein level was 
performed using a shareware ImageJ software (version 1.52q, 
bundled with Java 1.8.0_172; developer: NIH).
RAD51 foci assay. The HR pathway is active in the S and G2 
phases of the cell cycle to repair DSBs induced by IR (2,24‑26), 
and relies on RAD51, whose recruitment to a DSB site is 
mediated by BRCA1 and BRCA2. RAD51 recruitment can be 
WORLD ACADEMY OF SCIENCES JOURNAL  2:  19-27,  2020 21
typically detected in the form of nuclear foci upon immunos-
taining (25,27). The RAD51 irradiation‑induced foci assay has 
been widely used to detect HR defects both in cancer biopsy 
samples and in non-tumor cells of BRCA1/2 breast cancer 
patients (28‑30).
Sample preparation. The cells were switched to puro-
mycin‑free culture DMEM medium (Life Technologies) at the 
beginning of each experiment. Cells (n=200,000) were seeded 
in 2 ml culture medium in 6-well plates. Approximately 24 h 
after seeding, the cells were examined for subconfluency. To 
achieve a maximum number of cells in the S and G2 phases 
of the cell cycle, the cells were synchronized by the addi-
tion of the DNA polymerase inhibitor, aphidicolin (1 µg/ml, 
Sigma‑Aldrich) to the culture medium for 24 h. The cells were 
subsequently washed with PBS (1.78 g/l Na2HPO4; 0.42 g/l 
KH2PO4; 7.2 g NaCl, VWR) and incubated at 37˚C for 8 h with 
fresh culture medium.
Cell cycle analysis. The MCF10A control cells (empty 
vector‑transduced) were harvested at various time points 
following synchronization to evaluate the percentage of cells in 
each phase of the cell cycle. Cell permeabilization was achieved 
by fixation in 95% ethanol at ‑20˚C and the DNA was subse-
quently stained with propidium iodide (PI, Sigma‑Aldrich) in 
a hypotonic staining buffer containing 0.1% Sodium citrate, 
0.3% Triton X‑100, 0.01% PI and 0.002% ribonuclease A 
(all reagents were from Sigma‑Aldrich). The PI cell content 
was analyzed on a FACSCantoTM (BD Biosciences). Cells of 
interest were selected based on forward and side scatter area 
patterns. A non-synchronized sample was used as reference.
Irradiation and olaparib treatment. At 3 h following 
aphidicolin removal, the cells were irradiated with 2 Gy 
220 kV‑13 mA X‑rays to generate DSBs (SARRP unit, 
XSTRAHL Ltd.). The cells were subsequently incubated at 
37˚C for 5 h for optimal RAD51 foci formation. To determine 
this optimal time point, different time points varying between 
2 and 8 h were previously tested (data not shown).
Since cel ls defect ive in HR are sensit ive to 
poly(ADP‑ribose) polymerase (PARP) inhibitor (PARPi) 
drugs (31‑33), the PARPi, olaparib, was used to enhance the 
number of DSBs in S‑phase cells. To part of the cultures, 5 µM 
olaparib (Bio‑Connect) was added to the medium 1 h prior to 
irradiation, in order to block the repair of radiation-induced 
single‑strand breaks (SSBs). RAD51 foci formation was also 
evaluated in untreated cell cultures and in cultures exposed to 
olaparib alone. In total, 8 repeats were performed for each of 
the 4 experimental conditions (irradiated or sham-irradiated 
cells, with or without olaparib treatment).
The induction of DNA DSBs by IR was assessed by 
gamma‑H2AX staining as previously described (34) (Fig. S1). 
Inhibition by olaparib was confirmed by the PARP activity 
following exposure to H2O2 in the presence of olaparib, as 
previously described (35) (Fig. S2).
RAD51 foci immunostaining. Prior to RAD51 foci staining, the 
cells were harvested, cytospinned on polylysine-coated slides 
(VWR) and fixed in 3% paraformaldehyde (Sigma‑Aldrich) 
for 20 min. The slides were washed twice in PBS and antigen 
retrieval was achieved by incubation for 20 min in heated 
(95˚C) citrate buffer (0.02% citric acid, pH 6, Sigma‑Aldrich). 
The slides were subsequently washed and incubated with a 
blocking serum containing 1% BSA (Roche), 5% goat serum 
(Dako) and 0.2% Tween‑20 (Sigma‑Aldrich) in PBS. The slides 
were then incubated overnight at 4˚C with a RAD51 H‑92 rabbit 
primary antibody (dilution: 1:2,000, Santa Cruz Biotechnology, 
cat. no. sc‑8349), washed with PBS containing 3% Tween‑20 
(Sigma‑Aldrich), and incubated for 30 min at room tempera-
ture with a secondary antibody (goat anti‑rabbit; dilution: 
1:1,000, Thermo Fisher Scientific; cat. no. A32731). Finally, the 
slides were washed in PBS/3% Tween‑20 and mounted with 
200 ng/ml DAPI in fluoromount (Sigma‑Aldrich).
The slides were scanned using the Metacyte software 
module on a Metafer4 scanning platform (Axio Imager, 
Metasystems) at a x63 magnification. This software module 
enables automatic cell detection and foci counting according 
to set parameters, resulting in an unbiased data acquisition. 
The number of RAD51 foci was automatically scored in at 
least 500 cells for each experimental condition, and expressed 
as the number of RAD51 foci per cell (RAD51 foci/cell).
Micronucleus (MN) assay. Chromosomal damage was 
assessed with the MN assay as previously described (36). 
Briefly, the cells were seeded in 2 ml culture medium in 
6‑well plates (200,000 cells/well) 1 day prior irradiation. 
Subconfluent cultures of exponentially dividing cells were irra-
diated with doses of 0.2, 0.5, 1, 2 and 4 Gy, and cytochalasin B 
(2.25 µg/ml; Sigma‑Aldrich) was immediately added to block 
cytokinesis. The cells were maintained at 37˚C in a humidi-
fied 5% CO2 atmosphere incubator for 16 h. Sham-irradiated 
cultures were included in each experiment. The cells were 
then harvested and subjected to a cold hypotonic shock with 
0.075 M KCl, followed by overnight fixation in 3/1/4 meth-
anol/acetic acid/ringer solution (ringer: 9 g/l NaCl, 0.42 g/l 
Kcl and 0.24 g/l CaCl2). Subsequently, the cells were fixed in 
a 3:1 methanol/acetic acid solution. For further analysis, the 
cells were stained with DAPI (200 ng/ml; Sigma‑Aldrich). The 
slides were scanned at 10 X magnification with the MSearch 
software module of the Metafer 4 scanning system and the 
MNScore software (Metasystems). The automated image 
analysis system selects BN cells and determines the number 
of MN for each BN cell. BN cells and MN were manually 
examined for false positives and negatives. Two slides for 
each culture were automatically scanned and approximately 
400 BN cells were scored in each slide. All experiments were 
performed in duplicate. Each experiment was repeated thrice.
Cell viability assay. A protocol described previously was used 
for this assay (37,38). Briefly, following irradiation (doses of 
0.5, 1, 2, 3, 4, 6 and 8 Gy), the cultures were further incubated 
for 4 days at 37˚C until sham‑irradiated plates nearly reached 
confluence. The cells were fixed for 10 min in a solution of buff-
ered formalin (3.7%), washed with PBS (pH 7.3) and stained 
with a 0.01% crystal violet solution (Sigma‑Aldrich). The stain 
was dissolved overnight in 1 ml 10% sodium dodecyl sulfate 
(SDS). The optical density of the samples was measured with 
a spectrophotometer at 590 nm. All cell viability assays were 
performed in quadruplicate. Each experiment was repeated 
3 times.
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Statistical analysis. Differences in mean RAD51 foci, in 
micronucleus counts and in cell viability data were analyzed by 
one‑way analysis of variance (ANOVA). The Tukey's range test 
was applied to perform post‑hoc analysis of the significance of 
comparisons. A 5% alpha error threshold (P‑value <0.05) was 
applied to all analyses. Statistical inference was performed 
using the R software environment. For the Tukey post-hoc test, 
the multcompView package in R was used.
Results
Effects of RNAi. The lentivirus-mediated RNA interfer-
ence of BRCA1 and BRCA2 was confirmed at the RNA and 
protein levels by RT-qPCR analysis and western blot analysis. 
Compared to the control cells, 45 and 35% reductions in the 
BRCA1 and BRCA2 mRNA levels were achieved, respectively 
(Fig. S3). Notably, in experiments assessing knockout speci-
ficity, it was demonstrated that the knockdown of BRCA1 in 
the BRCA1i cells did not affect the mRNA levels of BRCA2 
(97% of controls), and the knockdown of BRCA2 in the 
BRCA2i cells did not affect the mRNA levels of BRCA1 (97% 
of controls). The quantification of the protein knockdown 
using ImageJ software revealed an estimated 70% reduction 
of BRCA1 in BRCA1i cells, and an estimated 51% BRCA2 
reduction in BRCA2i cells (Fig. 1).
Cell cycle analysis. The results of cell cycle analysis in 
non-synchronized cells, and in synchronized cells at various 
time points following aphidicolin removal are shown in Fig. 2. 
As an example, the histogram charts of all time points for 
one repeat are illustrated in Fig. 2A-E. The mean percentage 
(4 repeats) of cells in each phase of the cell cycle in a 
non-synchronized sample, and in synchronized cells at various 
time points (0, 2, 3 and 8 h) following aphidicolin removal is 
shown in Fig. 2F.
Synchronization with aphidicolin increased the number of 
cells in the S phase of the cell cycle. Immediately following 
aphidicolin synchronization, approximately 70% of the cells 
were at the beginning of the S phase, compared to 30% in 
non-synchonized cells. At 2 and 3 h following aphidicolin 
removal, the lowest number of cells in the G1 phase was 
achieved, while the number of cells in the S phase remained 
between 60 and 70%, compared to the non‑synchronized 
cultures. At 8 h following aphidicolin synchronization, the 
cells shifted towards the G2 and M phases of the cell cycle. 
Since the number of cells in the late S phase peaked at 2 
and 3 h following synchronization, these time points were 
selected for the addition of olaparib (2 h following the removal 
of aphidicolin) and irradiation (3 h following the removal of 
aphidicolin) to maximize the effects of these agents on RAD51 
foci formation.
RAD51 foci formation. Representative examples of the induc-
tion of RAD51 foci by radiation in the nuclei of MCF10A 
cells, with or without a knockdown of BRCA1 or BRCA2 are 
illustrated in Fig. 3. The mean number of RAD51 foci per cell 
in synchronized cell cultures, assessed in the 4 tested condi-
tions (irradiated or sham‑irradiated, with or without olaparib) 
is shown in Fig. 4. The significance values for all comparisons 
are listed in Table SI.
Control MCF10A cells. Compared to the cells not irradiated 
and not exposed to olaparib, exposure to IR induced marked 
and significant increases in the mean RAD51 foci/cell, both 
in the presence (~2.3‑fold) or absence (~1.9‑fold) of olaparib 
(Fig. 4, blue bars and Table SI).
The exposure of sham-irradiated control cells to olaparib 
did not significantly increase the number of foci/cell. 
Conversely, in the irradiated control cells, exposure to olaparib 
caused a small, yet significant increase in RAD51 foci/cell 
(~1.2‑fold; Fig. 4, blue bars and Table SI).
BRCA1i and BRCA2i cells. Compared to their respective 
controls, a significantly lower yield of RAD51 foci was 
observed in the irradiated BRCA1i and BRCA2i cells, exposed 
(BRCA1i cells, 49% reduction; BRCA2i cells, 60% reduction) 
or not (BRCA1i cells, 58% reduction; BRCA2i cells, 64% 
reduction) to olaparib (Fig. 4 and Table SI).
Compared to the BRCA1i or BRCA2i cells not irradi-
ated and not exposed to olaparib, exposure to IR did not 
induce statistically significant increases in the mean RAD51 
foci/cell, both in the presence or absence of olaparib (Fig. 4 
and Table SI).
Micronucleus assay. The spontaneous MN yield (mean 
number of micronuclei per 1,000 sham-irradiated binucleated 
cells ± SD) for the control, BRCA1i and BRCA2i cells was 
28.1±2.5; 31.7±4.2 and 26.0±1.7, respectively. There was no 
significant difference in the spontaneous MN values between 
the BRCA1i or BRCA2i cell lines and control MCF10A cells.
The MN dose-response curves in the control cells, and in 
the BRCA1i and BRCA2i cells are shown in Fig. 5. Compared 
to the irradiated controls, significantly higher MN yields were 
obtained in both the BRCA1i and BRCA2i irradiated cell lines. 
The BRCA1i cells were the most radiosensitive, resulting in a 
steeper, quasi-linear dose-response curve. The P-values for all 
the comparisons are listed in Table SI.
Cell viability assay. Cell viability/survival curves of knock-
down cell lines together with the control cell line are shown 
in Fig. 6. The BRCA1i and BRCA2i irradiated cells exhibited 
a dose-dependent decrease in survival, when compared to the 
Figure 1. Western blot analysis of BRCA1 and BRCA2 protein levels in 
BRCA1i, BRCA2i and control (CONBRCA) cell lines. Actinin was used as a 
protein loading control. The bar chart shows the relative protein expression 
(%), assessed using ImageJ software.
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control cells. The P-values for all the comparisons are listed 
in Table SI.
Discussion
The main aim of this in vitro study was to assess homologous 
recombination repair and radiosensitivity in human mammary 
cells showing reduced protein levels of wild-type BRCA 
proteins, a condition that may model the reduced protein 
expression observed in heterozygous cells of women carriers 
of BRCA1/BRCA2 mutations. A reduced BRCA expression, 
and in turn, an impaired DNA repair capacity may point to an 
increased risk of developing radiation-induced carcinogenesis 
in such women. One of the authors' concerns was that a BRCA 
mutation carrier receiving, for example, repeated mammog-
raphy screens each year, or adjuvant radiotherapy following 
surgical removal of a primary lesion, may be at increased 
risk of developing secondary, radiation-induced neoplasia. 
Thus, in this study, a dose of radiation was selected which is 
commonly administered to women receiving a single session 
of radiotherapy (2 Gy). In the experiments in this study, the 
non-tumorigenic and non-mammosphere-forming MCF10A 
cell line was selected, which is often used as in vitro model, 
together, with its in vitro-transformed derivative cell lines-to 
investigate the biology of non-neoplastic human mammary 
cells (39). These diploid cells have a relatively stable karyotype 
Figure 2. Cell cycle analysis. (A‑E) Representative histograms (one repeat) showing the number of MCF10A control cells in each phase of the cell cycle. 
(A) Non‑synchronized control cell culture; (B) cells immediately (0 h) following synchronization, and at (C) 2 h, (D) 3 h and (E) 8 h following synchronization. 
(F) Mean percentage of cells in each phase of the cell cycle prior to synchronization and at various time points following aphidicolin removal. Cells were 
stained with propidium iodide (PI). Horizontal axes (linear scale) show the PI content and vertical axes (linear scale) indicate cell counts. Means and standard 
error bars are based on 4 repeats. Equivalent patterns of cell cycle distribution were found in BRCA1i and BRCA2i cells.
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and form in vitro acinar structures that recapitulate many 
aspects of mammary gland architecture.
The cells were synchronized in the S and G2 phases for 
an optimal evaluation of the DNA repair capacity by homolo-
gous recombination, a pathway which involves both BRCA1 
and BRCA2. DSBs were induced by exposure to ionizing 
radiation. To increase the number of DSBs, olaparib was also 
used, which is a PARPi that transforms radiation-induced 
single-strand breaks into DSBs during the S phase of the cell 
cycle.
As expected, HR was involved in the repair of radia-
tion-induced DSBs in synchronized MCF10A cells, as shown 
by the highly significant increase of RAD51 foci yields in 
irradiated control cells, compared to their sham-irradiated 
counterparts. Conversely, exposure to IR did not increase 
the yield of RAD51 foci, either in BRCA1i or in BRCA2i 
cells. In fact, significantly lower yields of RAD51 foci were 
observed in the BRCA1i and BRCA2i cell lines compared 
to the irradiated control cells. The lack of induction of 
RAD51 foci in the BRCA1i and BRCA2i cells may suggest 
that the knockdown may phenotypically mimic BRCA haplo-
insufficiency in breast epithelial cells, where the presence 
of a single wild-type allele may result in increased DNA 
Figure 5. Micronucleus assay in BRCA1i (■), BRCA2i (●) and control (▲) 
MCF10A cells. Dose‑response curves of cells exposed to 0.25, 0.5, 1, 2 
and 4 Gy ionizing radiation. Data points are the mean values (± SD) of 3 
independent experiments performed in duplicate. With the exception of the 
0 Gy (BRCA1i and BRCA2i lines) and 0.25 Gy doses (BRCA2i line only), 
all data points of both curves (■,●) indicate significant differences compared 
to the control data points (▲) at the same radiation dose (detailed results of 
statistical analysis are shown in Table SI). Statistical analysis was carried out 
using one‑way ANOVA with Tukey's post‑hoc test. MN, micronuclei; BN, 
binucleate.
Figure 4. Mean number of RAD51 foci per cell (RAD51 foci/cell) in 
aphidicolin‑synchronized MCF10A control (blue bars), BRCA1i (orange 
bars) and BRCA2i (grey bars) cell lines. Cells were irradiated (IR) or 
sham‑irradiated (no IR), and exposed/not exposed to the PARP inhibitor 
olaparib (olaparib/no olaparib). Error bars indicate the standard errors of the 
means, based on 8 repeats. *P<0.00001 vs. irradiated controls not exposed 
to olaparib, **P=0.0001 (BRCA1i) or **P<0.00001 (BRCA2i) vs. irradiated 
controls exposed to olaparib, ***P<0.00001 vs. non‑irradiated controls not 
exposed to olaparib, #P<0.05 vs. irradiated controls not exposed to olaparib. 
Statistical analysis was carried out using one‑way ANOVA with Tukey's 
post-hoc test and the detailed results are shown in Table SI.
Figure 3. RAD51 foci in the nuclei of (A and D) control MCF10A cells, of (B and E) BRCA1i MCF10A cells and (C and F) BRCA2i MCF10A cells. (A‑C) Cells 
with DAPI‑stained nuclei (blue) containing green fluorescent RAD51 foci induced following ionizing radiation. (D‑F) Foci staining in sham‑irradiated cells. 
These images were obtained with a Metafer4 equipment (Metasystems).
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damage resulting from deficient HR repair, as suggested by 
Sedic and Kuperwasser (40).
Studies investigating the influence of BRCA1 and BRCA2 
on RAD51 foci formation and HR function have been previ-
ously performed using non-human, non-mammary cell lines 
such as CHO, DT40 and mouse embryonic stem cells. All 
studies have demonstrated an impaired function of HR path-
ways, resulting in a reduction in RAD51 foci formation in 
heterozygous cells (30,41‑44).
The results of studies focusing on the effects of BRCA1 
on both RAD51 foci formation and HR have been less 
univocal (43,44). In a study using lymphoblastoid cell lines of 
heterozygous BRCA1 mutation carriers, Vaclová et al could 
not directly demonstrate a decrease in RAD51 foci formation, 
compared to the controls, at 4 h following exposure to 10 Gy 
IR. However, they did observe a significant increase in staining 
intensity of yH2AX foci in the same heterozygous BRCA1 cells 
compared to controls 4 h following irradiation, thus suggesting 
an increase in the number of DSBs. They also argued that 
this result implies impaired HR in mutation carriers (29). 
Pathania et al did not detect a reduction in radiation-induced 
RAD51 foci in human mammary epithelial cells containing a 
BRCA1 mutation exposed to 10 Gy compared to control cells. 
However, the combined exposure to UV and IR did yield a 
significant reduction of RAD51 foci (45).
Notably, with one exception, these studies were performed 
in non-mammary cells. The authors of this study believe that 
experiments performed herein modeled more closely the 
cellular makeup of human breast cells.
Moreover, none of these studies considered the variation of 
HR-based DSB repair throughout the different phases of the 
cell cycle. It was demonstrated that 48% of non‑synchronized 
cycling MCF10A cells were in the G1 phase of the cell cycle, a 
phase during which HR cannot be activated due to the absence 
of the homologous sister chromatid. In the synchronized cell 
cultures, at the moment of irradiation approximately 90% of 
cells were in the S or G2 phases of the cell cycle, during which 
HR activation is maximal for repair of DSBs (2,46).
In order to activate the HR pathway more extensively, 
olaparib was added to the cultures prior to irradiation. A small, 
yet significant increase was observed in the number of RAD51 
foci in irradiated, olaparib-treated control cells compared to 
cells not exposed to olaparib. However, PARP inhibition did 
not significantly increase the yield of RAD51 foci in irradi-
ated BRCA1i or BRCA2i cells. The limited effect of olaparib 
treatment in the experiments in this study may be due to an 
exhaustion of HR capacity by aphidicolin synchronization 
and exposure to IR. Furthermore, it should be considered that 
PARP fulfills a number of different functions in the DNA 
damage response, including detection and signaling of DSBs 
and stabilization of stalled replication forks (47,48). It was 
hypothesized that in the experiments herein, PARP trapping, 
initiated by olaparib at the SSB site (47,49), may have partly 
impaired HR activation once the SSB is transformed in a DSB 
due to the replication fork collapse.
To investigate whether the impairment of HR shown by a 
decrease in RAD51 foci would result in increased chromo-
somal abnormalities, we have performed the micronucleus 
assay. Compared to controls, a marked and dose-dependent 
increase of micronucleus formation was observed in irradi-
ated cells harboring a BRCA1 or BRCA2 knockdown. This 
effect was more pronounced in BRCA1i cells likely because 
BRCA1 plays a broader role in DNA DSB repair, which 
includes the non‑homologous end‑joining pathway (1,2). 
This pathway is active also in the G1 phase of the cell 
cycle, and the micronucleus assay was performed in cycling 
MCF10A cells, of which a fraction of >40% was in the 
G1 phase.
The impaired DNA repair capacity in BRCA1i and BRCA2i 
cells also resulted in decreased cell survival compared to 
controls. In addition, in this case, the BRCA1i cells were 
affected by radiation to a greater extent, when compared to the 
BRCA2i cells.
In conclusion, this study demonstrated that in cells 
containing a knockdown for either BRCA1 or BRCA2, the 
HR pathway is impaired, resulting in a >50% reduction of 
RAD51 foci, in significant increases in MN yields and in 
decreased cell viability following exposure to ionizing radia-
tion, compared to the cells not subjected to knockdown. As in 
both BRCA1i and BRCA2i cell lines <50% of the protein is 
retained after lentiviral knockdown, the results obtained in the 
MCF10A cell line may mimic the situation in healthy carriers 
of a germline BRCA1/2 mutation. Therefore, the assessment 
of RAD51 foci in heterozygous BRCA1 and BRCA2 mutation 
carriers may be a useful strategy to measure radiosensitivity 
and HR capacity in these subjects. However, as the results 
of this study are preliminary, this hypothesis is currently 
being tested in breast epithelial cells and lymphocytes of 
BRCA1/BRCA2 women who may present impaired expres-
sion of BRCA due to the presence of germline heterozygous 
mutations in different functional domains of both genes. 
Information from these investigations will also be crucial 
to direct further research, ultimately aiming at improving 
protection strategies in subjects showing increased risk for 
radiation-induced carcinogenesis.
Figure 6. Cell viability assay of BRCA1i (■), BRCA2i (●) and control (▲) 
MCF10A cells. Dose‑response curves of cells exposed to 0.5, 1, 2, 3, 4, 6 
and 8 Gy ionizing radiation. Data points are the mean values (± SD) of 3 
independent experiments performed in duplicate. With the exception of the 2 
Gy and 8 Gy (BRCA2i line only), all data points of both curves (■,●) indicate 
significant differences compared to the control data points (▲) at the same 
radiation dose (detailed results of statistical analysis are shown in Table SI). 
Statistical analysis was carried out using one‑way ANOVA with Tukey's 
post-hoc test. A logarithmic graph is shown.
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